Lupin Inkomsten in het verleden

Verleden criteriumcontroles 5/6

Lupin is de winst gegroeid met een gemiddeld jaarlijks percentage van 39.4%, terwijl de Pharmaceuticals industrie de winst jaarlijks groeide met 13.4%. De inkomsten zijn gegroeid met een gemiddelde snelheid van 5.3% per jaar. Het rendement op eigen vermogen van Lupin is 16.9%, en het heeft een nettomarge van 12.3%.

Belangrijke informatie

39.4%

Groei van de winst

39.3%

Groei van de winst per aandeel

Pharmaceuticals Groei van de industrie17.5%
Inkomstengroei5.3%
Rendement op eigen vermogen16.9%
Nettomarge12.3%
Laatste winstupdate30 Sep 2024

Recente prestatie-updates uit het verleden

Recent updates

Lupin Limited Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Nov 10
Lupin Limited Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

With EPS Growth And More, Lupin (NSE:LUPIN) Makes An Interesting Case

Sep 17
With EPS Growth And More, Lupin (NSE:LUPIN) Makes An Interesting Case

Lupin Limited Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Aug 09
Lupin Limited Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Unpleasant Surprises Could Be In Store For Lupin Limited's (NSE:LUPIN) Shares

Aug 01
Unpleasant Surprises Could Be In Store For Lupin Limited's (NSE:LUPIN) Shares

Lupin Limited (NSE:LUPIN) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?

Jul 13
Lupin Limited (NSE:LUPIN) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?

Lupin's (NSE:LUPIN) Dividend Will Be Increased To ₹8.00

Jul 12
Lupin's (NSE:LUPIN) Dividend Will Be Increased To ₹8.00

These 4 Measures Indicate That Lupin (NSE:LUPIN) Is Using Debt Safely

Jun 15
These 4 Measures Indicate That Lupin (NSE:LUPIN) Is Using Debt Safely

Analysts Are Updating Their Lupin Limited (NSE:LUPIN) Estimates After Its Annual Results

May 09
Analysts Are Updating Their Lupin Limited (NSE:LUPIN) Estimates After Its Annual Results

With EPS Growth And More, Lupin (NSE:LUPIN) Makes An Interesting Case

May 08
With EPS Growth And More, Lupin (NSE:LUPIN) Makes An Interesting Case

Investor Optimism Abounds Lupin Limited (NSE:LUPIN) But Growth Is Lacking

Apr 20
Investor Optimism Abounds Lupin Limited (NSE:LUPIN) But Growth Is Lacking

Here's Why Lupin (NSE:LUPIN) Can Manage Its Debt Responsibly

Mar 03
Here's Why Lupin (NSE:LUPIN) Can Manage Its Debt Responsibly

Earnings Beat: Lupin Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Feb 10
Earnings Beat: Lupin Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Lupin Limited's (NSE:LUPIN) Share Price Could Signal Some Risk

Jan 19
Lupin Limited's (NSE:LUPIN) Share Price Could Signal Some Risk

Is Lupin (NSE:LUPIN) Using Too Much Debt?

Nov 10
Is Lupin (NSE:LUPIN) Using Too Much Debt?

Is Lupin (NSE:LUPIN) Using Too Much Debt?

Jun 23
Is Lupin (NSE:LUPIN) Using Too Much Debt?

Here's Why Lupin (NSE:LUPIN) Can Manage Its Debt Responsibly

Mar 24
Here's Why Lupin (NSE:LUPIN) Can Manage Its Debt Responsibly

Lupin's (NSE:LUPIN) Dividend Is Being Reduced To ₹4.00

Jul 08
Lupin's (NSE:LUPIN) Dividend Is Being Reduced To ₹4.00

Opbrengsten en kosten

Hoe Lupin geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.


Inkomsten en omzetgeschiedenis

NSEI:LUPIN Opbrengsten, kosten en inkomsten (INR Millions )
DatumInkomstenInkomstenG+A UitgavenR&D-uitgaven
30 Sep 24214,31326,26538,6640
30 Jun 24207,97122,63537,1960
31 Mar 24200,10819,14535,9300
31 Dec 23194,80117,91034,6470
30 Sep 23186,04913,31433,3940
30 Jun 23177,1199,71432,5040
31 Mar 23166,4174,30131,8450
31 Dec 22160,946-3,23931,0900
30 Sep 22159,33368230,8890
30 Jun 22158,791-21,59630,7580
31 Mar 22164,055-15,28030,8100
31 Dec 21163,052-5,49730,1510
30 Sep 21161,616-6,57029,7800
30 Jun 21159,05316,52129,0470
31 Mar 21151,63012,16529,1460
31 Dec 20152,26011,45830,3680
30 Sep 20149,777-1,60930,7070
30 Jun 20150,249-5,57231,4560
31 Mar 20153,748-3,99530,7440
31 Dec 19174,693-4,42835,4290
30 Sep 19176,8923,13834,9590
30 Jun 19172,8067,06834,3940
31 Mar 19146,6465,12129,6580
31 Dec 18163,114-4,66532,8750
30 Sep 18157,822-93131,7210
30 Jun 18157,82996031,0330
31 Mar 18157,7652,51330,7180
31 Dec 17159,23314,15030,3610
30 Sep 17164,30618,26430,7170
30 Jun 17167,69320,33630,5670
31 Mar 17173,67425,57530,4190
31 Dec 16173,91029,35128,2490
30 Sep 16164,55828,26526,3720
30 Jun 16154,91825,84124,5760
31 Mar 16141,31622,60722,9310
31 Dec 15131,05520,10636,5921,682
30 Sep 15127,27320,82335,4671,682
30 Jun 15125,79423,03534,6141,682
31 Mar 15127,70024,03218,5700
31 Dec 14128,12424,09232,7091,311
30 Sep 14126,56722,83932,3371,311
30 Jun 14121,51220,60131,6301,311
31 Mar 14112,86618,36430,8081,311
31 Dec 13107,51916,91528,011890

Kwaliteitswinsten: LUPIN heeft hoge kwaliteitsinkomsten.

Groeiende winstmarge: De huidige netto winstmarges (12.3%) LUPIN } zijn hoger dan vorig jaar (7.2%).


Analyse vrije kasstroom versus winst


Analyse van de winstgroei in het verleden

Winsttrend: De winst van LUPIN is de afgelopen 5 jaar aanzienlijk gegroeid met 39.4% per jaar.

Versnelling van de groei: De winstgroei van LUPIN over het afgelopen jaar ( 97.3% ) overtreft het 5-jarig gemiddelde ( 39.4% per jaar).

Winst versus industrie: De winstgroei LUPIN over het afgelopen jaar ( 97.3% ) overtrof de Pharmaceuticals -sector 20%.


Rendement op eigen vermogen

Hoge ROE: Het Rendement op eigen vermogen ( 16.9% ) van LUPIN wordt als laag beschouwd.


Rendement op activa


Rendement op geïnvesteerd vermogen


Ontdek sterk presterende bedrijven uit het verleden